List of Excipients in Branded Drug METHYLPREDNISOLONE SODIUM SUCCINATE

Generic Drugs Containing METHYLPREDNISOLONE SODIUM SUCCINATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	methylprednisolone sodium succinate	0143-9182	SODIUM PHOSPHATE DIBASIC DIHYDRATE
Hikma Pharmaceuticals USA Inc	methylprednisolone sodium succinate	0143-9182	SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Hikma Pharmaceuticals USA Inc	methylprednisolone sodium succinate	0143-9754	SODIUM HYDROXIDE
Hikma Pharmaceuticals USA Inc	methylprednisolone sodium succinate	0143-9754	SODIUM PHOSPHATE, DIBASIC
Hikma Pharmaceuticals USA Inc	methylprednisolone sodium succinate	0143-9754	SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

What are the Most Frequently-Used Excipients in METHYLPREDNISOLONE SODIUM SUCCINATE?

# Of NDCs	Excipient
2	BENZYL ALCOHOL
1	DISODIUM PHOSPHATE
5	LACTOSE MONOHYDRATE
8	SODIUM HYDROXIDE
2	SODIUM PHOSPHATE DIBASIC DIHYDRATE

Methylprednisolone Sodium Succinate Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

Methylprednisolone sodium succinate is an established injectable corticosteroid with limited active-ingredient patent protection and substantial opportunity in formulation execution. Commercial differentiation is most credible through preservative-free presentations, ready-to-use or ready-to-administer formats, improved reconstitution, container compatibility, supply reliability, and hospital procurement economics.

The principal product is Pfizer’s Solu-Medrol, marketed for intravenous or intramuscular administration. Multiple generic manufacturers supply equivalent products through abbreviated new drug applications (ANDAs). The product is not a biologic and does not face biosimilar competition. Its competitive risks arise from generic substitution, hospital contracting, shortage-driven procurement, and alternative corticosteroid products.

What is methylprednisolone sodium succinate used for?

Methylprednisolone sodium succinate is a water-soluble corticosteroid prodrug used when rapid parenteral administration is required. It is converted in vivo to methylprednisolone, the active glucocorticoid.

The FDA-approved labeling covers a broad range of inflammatory, allergic, rheumatic, dermatologic, respiratory, hematologic, gastrointestinal, and other steroid-responsive conditions. Dosing varies substantially by indication and severity. The product is administered intravenously or intramuscularly, with intravenous use often preferred when rapid systemic exposure is required. [1]

What dosage forms are commercially relevant?

Product characteristic	Commercial relevance
Sterile powder for reconstitution	Lower manufacturing complexity and longer stability potential
Dual-chamber or Act-O-Vial presentation	Reduces external diluent handling and preparation steps
Ready-to-use solution	Higher convenience but greater stability and packaging burden
IV and IM administration	Broad institutional use
Single-dose vial	Supports infection-control requirements
Preservative-free presentation	Important for neonates, pediatrics, intrathecal-risk avoidance, and sensitive patient populations
Multiple strengths	Supports emergency departments, operating rooms, intensive-care units, and hospital pharmacies

Solu-Medrol has historically been supplied in multiple strengths, including 40 mg, 125 mg, 500 mg, and 1,000 mg presentations. Exact excipients and diluent compositions vary by strength and manufacturer. Product labels must be reviewed at the National Drug Code level before procurement or formulation decisions. [1,2]

What excipients are used in methylprednisolone sodium succinate injections?

The excipient system is presentation-specific. The core formulation challenge is to maintain a sterile, rapidly reconstituted, chemically stable product while limiting particulate formation, pH drift, oxidation, adsorption, and compatibility failures.

Common excipient or formulation components may include:

• Water for injection in the supplied diluent.
• Phosphate salts or other buffering agents.
• Lactose or another bulking agent in selected presentations.
• Sodium hydroxide or hydrochloric acid for pH adjustment.
• Preservatives in selected multidose or lower-strength presentations, where permitted by the label.
• Nitrogen or other controlled-headspace strategies to reduce oxidative stress.
• Elastomer and container components selected for low adsorption and extractables control.

Lactose requires specific attention. Some methylprednisolone sodium succinate products identify lactose derived from bovine milk and carry a warning for patients with known or suspected hypersensitivity to cow’s milk components. A lactose-free product can therefore have a differentiated clinical and procurement profile, particularly in pediatrics and allergy-sensitive settings. [1,2]

How does the succinate salt affect excipient strategy?

Methylprednisolone sodium succinate has substantially greater aqueous solubility than methylprednisolone acetate. That difference enables parenteral use but creates formulation constraints related to ionic strength, pH, hydrolysis, and reconstitution behavior.

The formulation must control:

• Salt concentration and osmolality.
• Solution pH.
• Reconstitution time.
• Visible and subvisible particles.
• Degradation during storage.
• Compatibility with common IV fluids.
• Adsorption to syringes, tubing, and infusion bags.
• Stability after reconstitution or dilution.

A formulation that improves one parameter can impair another. For example, stronger buffering may improve pH control but increase ionic strength and alter compatibility with infusion systems.

What excipient strategy offers the strongest commercial opportunity?

The strongest opportunities are operational rather than pharmacologically novel. Hospitals purchase injectable corticosteroids based on availability, total preparation cost, product reliability, barcode integration, and contract pricing.

1. Preservative-free and lactose-free products

A preservative-free, lactose-free formulation can address patient-specific restrictions and reduce substitution barriers. The opportunity is strongest where the incumbent or low-cost generics have presentation-specific excipient warnings.

Commercial advantages include:

• Broader use in neonatal and pediatric settings.
• Reduced concern about benzyl alcohol or other preservatives.
• Avoidance of bovine-derived lactose where clinically relevant.
• Simplified formulary positioning.
• Potential premium pricing in specialty hospital channels.

The product must demonstrate equivalent quality, stability, sterility assurance, and labeling clarity. Excipient substitution alone does not create therapeutic equivalence; the sponsor still must satisfy FDA requirements for injectable generic approval or a separate 505(b)(2) pathway. [3]

2. Ready-to-use injectable solution

A ready-to-use solution can reduce pharmacy compounding and preparation time. It may be attractive in emergency departments, ambulances, operating rooms, and intensive-care units.

The tradeoff is higher technical risk. Compared with a lyophilized powder, a solution is more exposed to:

• Hydrolytic degradation.
• Oxidation.
• Light sensitivity.
• Container closure interactions.
• Temperature excursions.
• Microbial-control requirements.
• Shorter in-use stability.

A ready-to-use product has the strongest commercial case when it can demonstrate a measurable reduction in preparation steps, medication errors, pharmacy labor, or waste. A proprietary prefilled syringe, cartridge, or small-volume bag could support a 505(b)(2) strategy if the product offers a meaningful delivery-system or usability advantage.

3. Improved reconstitution and transfer systems

Reconstitution performance is a practical source of differentiation. A product that dissolves rapidly with low foaming, minimal residual material, and clear visual inspection can improve emergency use.

Potential approaches include:

• Dual-chamber vials.
• Integrated diluent systems.
• Pre-attached transfer devices.
• Low-dead-volume connectors.
• Terminally sterilized diluent compartments.
• Packaging that supports one-handed preparation.
• Instructions designed for rapid emergency use.

The principal regulatory burden is combination-product and container-closure characterization, not active-ingredient novelty. Device-related claims may be protectable through utility or design patents, but the overall commercial protection will depend on whether the delivery system is difficult to replicate.

4. Extended post-reconstitution stability

Many hospitals discard reconstituted or diluted injectable products because of limited stability or uncertainty about storage conditions. A formulation with validated longer in-use stability could reduce waste.

The opportunity depends on data at:

• Room temperature.
• Refrigerated conditions.
• Common IV diluents.
• Typical syringe and infusion-bag materials.
• Light-exposed conditions.
• Multiple container sizes.
• Relevant administration durations.

Any stability claim must align with FDA-approved labeling and institutional compounding requirements. Stability data alone may support procurement differentiation even if it does not create durable patent protection.

5. Compatibility-led product positioning

Compatibility with 0.9% sodium chloride, dextrose solutions, and common infusion devices is commercially relevant. Hospitals value products that integrate with existing protocols and do not require special tubing, filters, or dilution instructions.

A sponsor can create a procurement advantage through:

• Clear compatibility tables.
• Standardized concentrations.
• Low particulate burden.
• Reduced adsorption to common materials.
• Validated storage in automated dispensing and pharmacy systems.
• Consistent vial fill and reconstitution performance.

These attributes are often more important to hospital buyers than a small reduction in excipient cost.

How many patents protect methylprednisolone sodium succinate?

Methylprednisolone sodium succinate is an old small-molecule corticosteroid. The original active-ingredient and basic injectable formulation patents are no longer expected to provide meaningful exclusivity in the United States.

Protection category	Current commercial significance
Original methylprednisolone compound patents	Expired
Original sodium succinate injectable formulation patents	Expired or commercially exhausted
Solu-Medrol product exclusivity	Historical, not a current barrier to ANDA entry
Orange Book-listed formulation patents	No major current barrier is generally associated with the legacy product
Device or packaging patents	Possible for new presentations
Manufacturing-process patents	Possible but difficult to enforce against a different process
Method-of-use patents	Limited value for broad established corticosteroid indications
Regulatory exclusivity	No expected current exclusivity barrier for the legacy product

The relevant FDA reference product is Solu-Medrol, associated with NDA 011631 in FDA product databases. Generic sponsors generally compete through ANDA pathways rather than through biosimilar applications. [2,4]

A current freedom-to-operate analysis should distinguish between expired composition patents, abandoned applications, unexpired formulation claims, manufacturing claims, and patents directed only to packaging or delivery devices. Patent-family status also differs by jurisdiction.

When does methylprednisolone sodium succinate lose exclusivity?

The key U.S. exclusivity loss occurred decades ago. Generic competition is established, and the market is already characterized by multiple manufacturers and strengths.

The remaining commercial barriers are not conventional exclusivity barriers. They are:

• FDA approval and manufacturing compliance.
• Sterility and aseptic-processing controls.
• Reliable active pharmaceutical ingredient supply.
• Injectable shortage management.
• Hospital contracting.
• Product-specific labeling requirements.
• Container-closure and compatibility performance.
• Ability to maintain supply across all marketed strengths.

Because the product is genericized, a new entrant is more likely to compete on cost, availability, excipient profile, or presentation than on patent duration.

What is the Orange Book status of methylprednisolone sodium succinate?

The Orange Book identifies FDA-approved reference products and any relevant patent or exclusivity information. For a legacy product such as Solu-Medrol, the commercial market is principally generic and is not dependent on a live branded formulation patent.

The Orange Book should be used together with Drugs@FDA and DailyMed because:

• The Orange Book identifies approved products and listed patents or exclusivities.
• Drugs@FDA provides approval history and regulatory documents.
• DailyMed provides current manufacturer-specific labeling and excipient information.
• FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations identifies therapeutically equivalent products. [2,4,5]

A sponsor should not assume that the absence of a major Orange Book patent eliminates all IP risk. Separate patents may cover packaging, automated reconstitution devices, manufacturing controls, or a new ready-to-use presentation.

Are there Paragraph IV challenges for methylprednisolone sodium succinate?

Paragraph IV litigation is unlikely to be the central market event for this product because the principal U.S. products are long-established and generic entry has already occurred. New ANDA filings may still create patent-certification issues if a listed patent exists for a particular reference presentation, but the expected dispute profile is materially lower than for recently approved small-molecule drugs.

The more relevant risks are:

• FDA deficiency letters.
• Sterility failures.
• Product recalls.
• Manufacturing-site disruption.
• Shortages.
• Therapeutic-equivalence disputes.
• Contract displacement by lower-cost suppliers.

For a new delivery system, litigation risk could shift from active-ingredient patents to device, packaging, and formulation patents.

What patent litigation affects methylprednisolone sodium succinate?

No major, current branded patent litigation is generally associated with the mature U.S. methylprednisolone sodium succinate market. The litigation profile is more likely to involve product liability, manufacturing quality, labeling, or procurement disputes than a high-value Paragraph IV campaign.

A new entrant should monitor:

• ANDA litigation listed in FDA or court records.
• District Court cases involving formulation or container patents.
• Patent Trial and Appeal Board proceedings.
• Recall notices.
• FDA warning letters involving injectable corticosteroid manufacturing.
• State and federal purchasing disputes.

The absence of major current litigation improves entry prospects but also indicates that price competition can be severe.

How does methylprednisolone sodium succinate compare with competing corticosteroids?

Product	Active ingredient	Main commercial distinction	Excipient and formulation opportunity
Solu-Medrol and generics	Methylprednisolone sodium succinate	Rapid parenteral corticosteroid use	Preservative-free, lactose-free, ready-to-use, compatibility
Depo-Medrol and generics	Methylprednisolone acetate	Less water-soluble depot suspension	Suspension stability, injection-site performance
Solu-Cortef and generics	Hydrocortisone sodium succinate	Injectable hydrocortisone	Reconstitution, dose convenience, supply reliability
Dexamethasone sodium phosphate	Dexamethasone phosphate	Potent corticosteroid with broad injectable use	Small-volume delivery, preservative profile, ready-to-use packaging
Prednisolone sodium phosphate	Prednisolone phosphate	Alternative corticosteroid formulation	Oral and injectable convenience depending on product

The competitive choice depends on potency, indication, onset, clinician familiarity, dosing protocol, hospital contract status, and availability. Methylprednisolone sodium succinate has a defensible position where institutions already standardize its use and value multiple strengths.

What licensing deals and partnerships are commercially relevant?

Licensing opportunities are more likely to involve manufacturing and delivery infrastructure than core drug substance rights. Relevant structures include:

• Contract manufacturing of sterile injectable product.
• In-licensing of a ready-to-use presentation.
• Regional commercialization agreements.
• Hospital-distributor partnerships.
• Dual sourcing of active pharmaceutical ingredient.
• Device licensing for integrated reconstitution.
• Co-development of prefilled syringes or cartridges.
• Authorized generic arrangements.

A license is most attractive when it delivers one of four assets: an approved product, validated sterile manufacturing capacity, differentiated packaging, or established hospital distribution. A license covering only the legacy active ingredient has limited strategic value.

What generic launch scenarios exist?

Low-cost powder entrant

This is the fastest and lowest-risk strategy. The sponsor markets standard strengths with conventional reconstitution and competes on price and supply. Margins may be thin, but the product can gain share through hospital tenders.

Premium excipient entrant

A lactose-free, preservative-free, or otherwise differentiated formulation targets pediatric, neonatal, specialty, and hospital pharmacy segments. The sponsor may obtain better net pricing but must generate clear formulary value.

Ready-to-use entrant

A prefilled syringe or ready-to-administer solution targets emergency and procedural settings. The product has stronger differentiation but higher development, packaging, and stability costs.

Supply-security entrant

The sponsor competes through dual API sourcing, domestic fill-finish, high service levels, and consistent availability. This strategy becomes valuable when competitors experience shortages or manufacturing interruptions.

What is the revenue exposure for manufacturers?

Methylprednisolone sodium succinate is a mature hospital injectable market. Revenue is exposed to generic price erosion, tender concentration, and product availability. A manufacturer should evaluate revenue by strength rather than treating the product as a single market.

The 125 mg strength may have strong emergency and inpatient demand. The 500 mg and 1,000 mg strengths support high-dose hospital use but may have lower unit volumes and greater budget impact. The 40 mg strength may carry specific excipient and pediatric-use considerations.

Commercial forecasting should model:

• Units by strength.
• Average selling price by channel.
• Hospital contract win rate.
• Wholesale acquisition cost.
• Shortage-related price volatility.
• Manufacturing yield.
• Fill-finish capacity.
• Product waste after reconstitution.
• Distributor and group-purchasing-organization discounts.

The largest value opportunity may come from reducing hospital preparation labor and waste rather than increasing vial price.

How strong is the patent estate for methylprednisolone sodium succinate?

The legacy patent estate is weak as a barrier to generic entry. Patent strength is more credible in newly engineered delivery systems, provided the claims cover a reproducible technical advantage and survive obviousness challenges.

Potentially defensible claim areas include:

• Specific excipient ratios that improve stability.
• Defined pH and osmolality ranges.
• Low-particulate compositions.
• Preservative-free liquid formulations.
• Lactose-free lyophilized compositions.
• Dual-chamber packaging.
• Prefilled syringe systems.
• Reconstitution devices.
• Container-closure combinations.
• Manufacturing processes that reduce degradation or aggregation.

Process patents are difficult to monetize if competitors can use a different process to make an equivalent product. Device and packaging patents can be stronger commercially when the presentation is tightly integrated into hospital workflow.

Key Takeaways

• Methylprednisolone sodium succinate is a mature, genericized injectable corticosteroid.
• The original active-ingredient and basic formulation patent barriers have expired.
• The product is not subject to biosimilar competition.
• The strongest commercial opportunities are preservative-free, lactose-free, ready-to-use, and reconstitution-optimized presentations.
• Hospital value depends on preparation time, waste, compatibility, availability, and contract economics.
• Orange Book and FDA regulatory review should be combined with current DailyMed labels because excipients vary by manufacturer and strength.
• New IP is more credible around delivery devices, packaging, stability, and manufacturing than around methylprednisolone sodium succinate itself.
• Generic launch risk is primarily price erosion, supply disruption, regulatory execution, and hospital procurement pressure.
• Licensing value is concentrated in approved sterile capacity, differentiated presentations, and distribution access.

FAQs

Is methylprednisolone sodium succinate protected by active U.S. patents?

The legacy active ingredient and basic injectable formulation are not expected to have meaningful current patent protection. New patents may cover packaging, devices, formulations, or manufacturing processes.

Can a company launch a lactose-free methylprednisolone sodium succinate product?

Yes, provided the sponsor satisfies the applicable FDA approval pathway and demonstrates product quality, stability, sterility, and therapeutic equivalence or clinical support appropriate to the regulatory route.

Is methylprednisolone sodium succinate a biosimilar product?

No. It is a chemically synthesized small molecule. Generic applicants use the ANDA pathway rather than the biosimilar pathway.

Which excipient creates the clearest differentiation opportunity?

Lactose is one of the clearest opportunities because some product labels identify bovine-milk-derived lactose. Preservative-free formulations and improved reconstitution systems also have meaningful institutional value.

What is the highest-value formulation opportunity?

A preservative-free, lactose-free, ready-to-administer product with validated stability, broad IV compatibility, and integrated preparation features has the strongest potential differentiation, although it also has the highest development and packaging burden.

References

1. Pfizer Inc. (2024). Solu-Medrol (methylprednisolone sodium succinate) for injection: Prescribing information. U.S. Food and Drug Administration.

2. U.S. National Library of Medicine. (2024). DailyMed: Methylprednisolone sodium succinate injection product labeling. National Institutes of Health.

3. U.S. Food and Drug Administration. (2017). Bioequivalence recommendations for methylprednisolone sodium succinate injection. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. Center for Drug Evaluation and Research.